New CAR-T therapy targets Hard-to-Treat blood cancers in early trial
NCT ID NCT06730256
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This early-phase study tests a new treatment called CT0596 CAR-T cells for people with multiple myeloma or plasma cell leukemia that has come back or not responded to standard therapies. The main goals are to check safety and find the right dose. About 24 adults will take part, and they will be followed for up to 15 years to monitor long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.